Speaker Profile
PhD, Project Manager and Senior Scientist, NASA
Biography
Dr. Costes, boasts a rich background in research leadership, spanning renowned institutions like the National Cancer Institute and the Lawrence Berkeley National Lab. He's also the cofounder and former CEO of Exogen Biotechnology Inc. Currently, Dr. Costes serves as the Chief for the Space Biosciences Research Branch and leads the Ames radiation biophysics laboratory at NASA Ames Research Center. Moreover, he manages all Open Science databases within the NASA Biological and Physical Science Division, overseeing initiatives in systems biology research, AIML modeling, and software development for the Open Science Data Repositories, including GeneLab and ALSDA. These repositories grant crucial access to spaceflight related data and samples. Beyond NASA, Dr. Costes is as a member of the White House's Cancer Cabinet, where he spearheads projects like Image Processing and Data Storage Frameworks under the Data Innovation Task Force, making significant strides in data-driven healthcare solutions and scientific advancements.
Talk
NASA Open Science Data Repositories (OSDR) for Space Biology
Addressing deep space mission challenges, NASA's Open Science Data Repositories (OSDR) facilitate open access to space biology data spanning microbes to humans, including all omics, physiological and phenomics data. OSDR ensures data discoverability and reproducibility, supporting experiments on genetic resilience to the space environment and advancing AI in space biology research.
AI and Data Sciences Showcase:
NASA
NASA Ames' Space Biosciences Division confronts the formidable challenges of spaceflight, where lower gravity, limited resources, and higher radiation levels pose significant risks to all forms of life. Addressing these issues is crucial for successful exploration of the moon, Mars, and beyond.
Session Abstract – PMWC 2024 Silicon Valley
The PMWC 2024 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
